Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
View Patent ↗Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities.
1. A method of restoring photosensitivity to retinal neurons of a subject suffering from vision loss or blindness, which method comprises: (a) delivering to a retina of said subject in which photoreceptors are degenerating or have already died a nucleic acid vector comprising a nucleic acid encoding a polypeptide of SEQ ID NO: 3 or a polypeptide having 98% or 99% sequence identity thereto, operably linked to a promoter sequence; and (b) expressing said polypeptide in said retinal neurons, wherein the expression of the polypeptide renders said retinal neurons photosensitive, thereby restoring photosensitivity to said retinal neurons.
2. The method of claim 1 , wherein the nucleic acid vector is a recombinant adeno-associated virus (rAAV) vector.
3. The method of claim 2 , wherein the rAAV vector is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6.
4. The method of claim 1 , wherein the promoter is a constitutive promoter.
5. The method of claim 1 , wherein the promoter is selected from the group consisting of a hybrid CAG promoter, a CMV promoter, an mGluR6 promoter, a Pcp2 (L7) promoter and a neurokinin-3 (NK-3) promoter.
6. The method of claim 1 , wherein the nucleic acid vector comprises a CAG promoter, a woodchuck posttransciptional regulatory element (WPRE) and a bovine or human growth hormone polyadenylation sequence.
7. The method of claim 1 , wherein the method increases visual evoked potential (VEP) in a visual cortex of the subject.
8. The method of claim 1 , wherein the vision loss or blindness is a result of a degenerative disease.
9. The method of claim 8 , wherein the disease is retinitis pigmentosa or age-related macular degeneration.
10. The method of claim 1 , wherein the subject is human.